Glaxosmithkline Biologicals Sa

Irm LLC

Novartis Ag

David Skibinski

Manmohan Singh

Derek T O'Hagan

Alex Cortez

Xiaoyue Zhang

Yongkai Li

Siddhartha Jain

Tom Yao Hsiang Wu

Nicholas M Valiante

Yefen Zou

Barbara Baudner

Francesco Doro

Mildred Ugozzoli

Pranab Mishra

Kathy Yue

Simona Cianetti

Donatello Laera

Sandra Nuti

Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.

Combination vaccines with lower doses of antigen and/or adjuvant

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Compounds and compositions as TLR activity modulators

The invention utilizes the techniques and instruments which are typically used in flow cytometry (FC) as a tool for analyzing adsorbed materials. Thus the invention provides a method for analyzing a component which is adsorbed to an insoluble metal salt, comprising steps of: (i) labelling the adsorbed component with a binding reagent; and (ii) analyzing the labelled adsorbed component by flow cytometry.

Flow cytometry analysis of materials adsorbed to metal salts

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

Homogenous suspension of immunopotentiating compounds and uses thereof

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: Xis N; Xis N Or CR; Xis &#x2014;CR&#x2550;CR. 

Growing community of inventors

Singapore, Singapore

David Skibinski